Journal of Drugs in Dermatology - Temozolomide vs. dacarbazine in stage IV metastatic melanoma
November 1, 2005 -- This study is currently recruiting patients. Sponsors and Collaborators. Schering-Plough European Organization for Research and Treatment of Cancer....
PR Newswire - Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity
March 10, 2008 -- GENEVA, Switzerland, March 10 /PRNewswire-FirstCall/ -- Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) today announced that ANAVEX...
Journal of Drugs in Dermatology - Evaluating the antitumor activity of MEDI-522 with or without dacarbazine in patients with metastatic melanoma
March 1, 2004 -- This study is currently recruiting patients. Sponsored by MedImmune, Inc. The primary objectives of this study are to explore the antitumor...
Business Wire - AmpliMed Begins Patient Enrollment for Phase I/II Trial of Amplimexon plus Dacarbazine for Treatment of Malignant Melanoma
July 13, 2005 -- TUCSON, Ariz. -- AmpliMed today announced that the Company has begun to enroll patients in a new clinical trial that will evaluate its lead...
Business Wire - AmpliMed Announces Interim Phase I/II Trial Results for Amplimexon plus Dacarbazine for Treatment of Malignant Melanoma; Encouraging Data Presented at...
September 14, 2006 -- NOORDWIJK, The Netherlands & TUCSON, Ariz. -- AmpliMed today announced interim results from the ongoing Phase I/II clinical trial of its lead...
Skin & Allergy News - Tremelimumab doesn't live up to standard chemo
July 1, 2008 -- CHICAGO -- Add tremelimumab monotherapy to the list of treatments that showed potential for improving metastatic melanoma survival but have failed...
Journal of Drugs in Dermatology - Oncophage for metastatic melanoma
April 1, 2008 -- Antigenics, Inc recently announced the completion and publication of results from its phase 3 trial of Oncophage[R] (vitespen), a cancer vaccine, in...
M2 Presswire - CHAT LIVE in the only dedicated CHAT ROOM for Anavex Life Sciences Corp. (OTCBB: AVXL) shareholders!
March 11, 2008 -- M2 PRESSWIRE-11 March 2008-Stockwire.com: CHAT LIVE in the only dedicated CHAT ROOM for Anavex Life Sciences Corp. (OTCBB: AVXL)...
Business Wire - Phase II Study of IMC-1121B for Advanced Malignant Melanoma Commences Patient Enrollment
December 13, 2007 -- NEW YORK -- ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel cancer therapeutics, today...
Business Wire - Specialists at Moores UCSD Cancer Center Evaluate New Option for Treating Advanced Melanoma
December 11, 2007 -- San Diego-Area Residents May Be Eligible to Participate in a Clinical Research Study SAN DIEGO -- Melanoma specialists at Moores UCSD Cancer Center...
